Sun Life Financial Inc.

Sun Life reported underlying net income of CAD 1.12 billion, up from CAD 1.02 billion last year, and underlying EPS of CAD 2.02, up 13% year over year. Underlying ROE was 19.1%, reported net income was CAD 1.01 billion versus CAD 716 million a year ago, LICAT was 145%, and holding company cash was CAD 2.3 billion. Canada underlying net income was CAD 427 million, up 23%; Sun Life Asset Management underlying net income was CAD 262 million, up 4%; U.S. underlying net income increased 15%; and Asia underlying net income increased 21%. For guidance and outlook, management reiterated medium-term targets including underlying EPS growth of 10%, underlying ROE of 20%, a dividend ratio of 40%-50%, and organic capital generation guidance of 30%-40%. They also said U.S. dental should see gradual improvement over time, but the state/Medicaid business will remain a struggle for a number of years and the actions being taken are unlikely to fully offset near-term volume pressure.

Kevin Strain framed the quarter as evidence that Sun Life is becoming a more diversified, global, and growth-oriented company. He emphasized broad-based earnings strength across Canada, Asia, U.S. health and risk solutions, and accelerating asset management momentum, while noting the company is on track against medium-term objectives. His tone was confident and constructive, especially around capital strength, AI/digital initiatives, and the ability to keep returning capital while investing for growth.

Tim Deacon highlighted the quarter’s hard numbers and bridge to reported results: underlying net income of CAD 1.12 billion, underlying EPS of CAD 2.02, and reported net income of CAD 1.01 billion. He said the gap to reported earnings was mainly from acquisition and integration costs in SLC in the U.S., intangible amortization, and modestly unfavorable net market impacts. On capital, he noted LICAT improved to 145% partly because of a CAD 750 million subordinated debt issuance, book value per share rose 3% to CAD 42.49, financial leverage was 23.8%, organic capital generation was 41%, total CSM was CAD 15.3 billion, and the company returned about half a billion dollars to shareholders via dividends while buying 0.8 million shares under the renewed NCIB.

Analysts focused heavily on U.S. stop loss and dental, asking why stop loss earnings did not rise more with strong sales and whether seasonal reserve buildup was masking performance. Management said the Q2 unfavorable morbidity line was mostly expected IBNR reserve buildup and that stop loss loss ratios remained stable in the mid-70s, while lower employee benefits earnings and a strong prior-year quarter also affected comparisons. On dental, management said Medicaid and government volume headwinds will continue to suppress earnings this year and that the business mix shift toward commercial dental will take one to two years, with the state business remaining difficult for several years. Questions on Asia centered on Hong Kong MCV exposure and new business CSM margins; management said MCV is about 30% of Hong Kong sales, roughly 10% of the high-net-worth business, and that current margin levels are appropriate in a competitive environment.